Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

The article is available online at http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2007-0 6- 095646v1. The analysis will also be published in a future print edition of Blood.

About PNH

PNH is an acquired genetic blood disorder defined by hemolysis, in which patients' red blood cells are destroyed by complement, a component of the body's immune system. PNH is a rare disease that affects an estimated 8,000 to 10,000 people in North America and Europe.(13) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's.(3) Approximately ten percent of all patients first develop symptoms at 21 years of age or younger.(2) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years.(4) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis.(13,4)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS).(14,15,16,17) In patients with thrombosis of unknown origin, PNH may be an underlying cause.(2,18)

Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk.(2,18)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commi
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 /PRNewswire/ ... announced the addition of Jain PharmaBiotech,s new ... Markets, and Companies" to their offering. ... transdermal drug delivery - an approach used ... therapeutic use as an alternative to oral,intravascular, ...
(Date:8/4/2015)... Concord Medical Services Holdings Limited ("Concord Medical", or the "Company") ... operator of the largest network of radiotherapy and diagnostic imaging ... will release its financial results for the second quarter of ... Management will hold a conference call to discuss the ... 18, 2015 (8:00 p.m. in Beijing / ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... The American College of Medical Genetics (ACMG) ... decision to make Critical Congenital Cyanotic Heart Disease (CCCHD) ... Secretary,s Advisory Committee on Heritable Disorders in Newborns and ... MD, FACMG had made the recommendations to Secretary Kathleen ...
... 2011 Visionsense Corp announces an unique milestone this ... 500th neurosurgical procedure with the VSii system. ... Vice-Chairman, Dept of Neurosurgery at Emory University and Professor ... of a pituitary adenoma in the morning of September ...
Cached Medicine Technology:American College of Medical Genetics Applauds HHS Secretary's Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease 2
(Date:8/4/2015)... , ... August 04, 2015 , ... ... which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their collegiate ... successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in ... millions of women every year. Dr. Angela DeRosa, DO, MBA, CPE aka ... therapies, takes the scary unknown out of menopause. , Myth #1: Menopause only ...
(Date:8/4/2015)... Diego, CA (PRWEB) , ... August 04, 2015 ... ... the Rise of Local Food,” scheduled for Nov. 3 – 4, 2015, at ... grow food sustainably, create new businesses, improve food access, and manage resources efficiently ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... 24/7 ... County, Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of ... indicate that 24/7 Care At Home’s agency is well on the path to meeting ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... label design, product packaging, and fulfillment services, joined over 200 other Long Island-based ... was held on Tuesday, July 28th at Jones Beach State Park in Wantagh, ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2
... President Obama and Secretary of State Clinton on today,s nomination ... the Global AIDS Coordinator (OGAC). AIDS Action is pleased ... led by such an accomplished HIV medical expert with extensive ... including the epidemic here in the United States. We ...
... 2009 (BRONX, NY) A laboratory study by researchers ... that an anti-cancer compound studied for treating blood cancers may ... The work is reported in the April 28th online edition ... neck cancer refers to tumors in the mouth, throat, or ...
... Findings from clinical studies used to gain Food and ... most patients with depression, according to a report led by ... in the May issue of the American Journal of ... people with depression qualify for these studies, and those who ...
... With growing concerns about the current spread of ... face masks protect against swine flu?"Tony Hanson, Managing Director ... an innovative, technologically advanced system of medical face masks ... this time it is believed that the current strain ...
... Inc. today announced that it named Dr. Robert Ruffolo, ... leader in pharmaceutical research to its Scientific Advisory Board. ... Development in 2008, and currently serves as a consultant ... and has been responsible for all pharmaceutical research and ...
... Embrace Use of Targeted Agents Despite Their High ... WALTHAM, Mass., April 28 Decision Resources, one ... focusing on pharmaceutical and healthcare issues, finds that ... Indian brand/generics (capecitabine) will dominate the Indian colorectal ...
Cached Medicine News:Health News:AIDS Action Applauds Selection of Dr. Eric Goosby as Global AIDS Coordinator 2Health News:Experimental drug shows promise against head and neck cancer 2Health News:Are we cherry picking participants for studies of antidepressants? 2Health News:Will Face Masks Protect Against Swine Flu? 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 3Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2
... the only dura material versatile enough for ... closure, and in cases where biological fixation ... in cases requiring an immediate watertight seal ... biological fixation and sealing are key factors ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Medicine Products: